Literature DB >> 8549098

Sjögren's syndrome and hepatitis C virus infection.

J M Durand1, P Lefevre, G Kaplanski, F Retornaz, E Cretel, C Chaussegros, C Trepo, J Soubeyrand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8549098     DOI： 10.1007/bf02208157

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  7 in total

1.  HCV and Sjögren's syndrome.

Authors:  A Aceti; G Taliani; M Sorice; M A Amendolea
Journal:  Lancet       Date:  1992-06-06       Impact factor: 79.321

2.  Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report.

Authors:  J H Hoofnagle; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; M Peters; J G Waggoner; Y Park; E A Jones
Journal:  N Engl J Med       Date:  1986-12-18       Impact factor: 91.245

3.  Sjögren's syndrome. Proposed criteria for classification.

Authors:  R I Fox; C A Robinson; J G Curd; F Kozin; F V Howell
Journal:  Arthritis Rheum       Date:  1986-05

4.  Labial salivary gland biopsy in Sjögren's disease.

Authors:  D M Chisholm; D K Mason
Journal:  J Clin Pathol       Date:  1968-09       Impact factor: 3.411

5.  Hepatitis C virus and Sjögren's syndrome.

Authors:  X Mariette; M Zerbib; A Jaccard; C Schenmetzler; F Danon; J P Clauvel
Journal:  Arthritis Rheum       Date:  1993-02

6.  PCR detection of HCV RNA among French non-A, non-B hepatitis patients.

Authors:  J Li; L Vitvitski; S Tong; C Trépo
Journal:  Arch Virol Suppl       Date:  1992

7.  Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease.

Authors:  J Haddad; P Deny; C Munz-Gotheil; J C Ambrosini; J C Trinchet; D Pateron; F Mal; P Callard; M Beaugrand
Journal:  Lancet       Date:  1992-02-08       Impact factor: 79.321
  7 in total
  1 in total

1.  Sjögren's syndrome: History, clinical and pathological features.

Authors:  A L Parke; W W Buchanan
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.